Short Interest in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Decreases By 34.3%

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the target of a large decline in short interest during the month of April. As of April 15th, there was short interest totaling 32,806 shares, a decline of 34.3% from the March 31st total of 49,927 shares. Based on an average trading volume of 40,565 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.3% of the shares of the stock are short sold.

Institutional Trading of Lixte Biotechnology

A number of large investors have recently added to or reduced their stakes in LIXT. Axxcess Wealth Management LLC bought a new stake in Lixte Biotechnology in the 4th quarter worth approximately $54,000. Geode Capital Management LLC boosted its holdings in shares of Lixte Biotechnology by 25.9% in the 4th quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock worth $205,000 after purchasing an additional 10,722 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Lixte Biotechnology by 47.0% in the 4th quarter. Renaissance Technologies LLC now owns 107,500 shares of the company’s stock worth $422,000 after purchasing an additional 34,350 shares during the period. DRW Securities LLC boosted its holdings in shares of Lixte Biotechnology by 11.6% in the 4th quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock worth $213,000 after purchasing an additional 5,645 shares during the period. Finally, Federation des caisses Desjardins du Quebec boosted its holdings in shares of Lixte Biotechnology by 83.6% in the 4th quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock worth $367,000 after purchasing an additional 42,530 shares during the period. Institutional investors own 5.10% of the company’s stock.

Lixte Biotechnology Price Performance

NASDAQ:LIXT remained flat at $3.50 during trading hours on Thursday. The company’s stock had a trading volume of 14,684 shares, compared to its average volume of 34,114. Lixte Biotechnology has a 1-year low of $0.64 and a 1-year high of $6.26. The company’s 50 day moving average price is $3.07 and its 200 day moving average price is $3.61. The company has a market capitalization of $40.67 million, a PE ratio of -2.82 and a beta of 0.93.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lixte Biotechnology in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.